NASDAQ$AVIR
Atea Pharmaceuticals Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Atea Pharmaceuticals reported Q3 2025, a net loss of $42M.
For Q3 2025, Atea Pharmaceuticals reported a net loss of $42M. Management discussed operating trends, liquidity, and priorities as disclosed in the quarterly filing.
- Net loss $42M.
- Atea Pharmaceuticals updated strategic and capital priorities in the filing.
- Atea Pharmaceuticals updated strategic and capital priorities in the filing.
Headline financials
Revenue & EPS history
Atea · Revenue · Quarterly
$0
Forward guidance
The filing discusses Atea Pharmaceuticals's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.
Tailwinds
- Atea Pharmaceuticals cited execution on strategic priorities in the filing.
- Balance sheet and liquidity support continued operations.
- Pipeline milestones remain the primary value driver.
Headwinds
- GAAP profitability remained under pressure in the quarter.
- Macro, competitive, and cost pressures may affect margins.
- Segment mix and one-time items can affect comparability.
- Clinical-stage spend continues ahead of commercial revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+0.1%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.2%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+16.1%
Q1 2021
Best reaction
-16.2%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +11.1% | +15.1% | +8.7% | |
| Q3 2025 | -12.1% | -12.9% | -10.0% | |
| Q2 2025 | -2.6% | +1.2% | -2.6% | |
| Q1 2025 | +2.2% | +4.0% | +16.4% | |
| Q4 2024 | -0.3% | +3.3% | -7.0% | |
| Q3 2024 | -2.2% | -7.0% | -17.9% | |
| Q1 2024 | -8.2% | -9.7% | -8.4% | |
| Q4 2023 | -5.5% | -11.4% | -11.4% | |
| Q3 2023 | -10.7% | -14.0% | -10.1% | |
| Q2 2023 | +4.1% | +0.3% | -3.5% | |
| Q1 2023 | -1.2% | -3.0% | +35.8% | |
| Q4 2022 | -8.7% | -0.8% | -8.1% | |
| Q3 2022 | -12.4% | -14.4% | -24.0% | |
| Q2 2022 | -3.5% | -4.3% | -11.7% | |
| Q1 2022 | +12.9% | +36.8% | +52.7% | |
| Q4 2021 | +1.4% | -9.7% | +11.1% | |
| Q3 2021 | +6.5% | +6.5% | -25.3% | |
| Q2 2021 | -16.2% | -12.9% | -13.4% | |
| Q1 2021 | +16.1% | +18.7% | +20.4% | |
| Q2 2020 | +5.3% | -1.4% | -55.0% | |
| Q4 2020 | +5.3% | -1.4% | -55.0% | |
| Q1 2020 | +7.2% | +10.6% | +73.1% | |
| Q4 2019 | +7.2% | +10.6% | +73.1% | |
| Q3 2020 | +7.2% | +10.6% | +73.1% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro